Article record

他汀类药物使用与接受帕博利珠单抗治疗的复发/转移性头颈部鳞状细胞癌的无进展生存期相关。

Statin Use Is Associated With Progression-Free Survival for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab.

临床研究咽喉科IF 2.5Q1

文献信息

PMID	42712089
原文	在 PubMed 查看原文 ↗
发表日期	2026
作者	Angeline A Truong 查看其他 12 位作者 Savinnie Ho；Rex H Lee；Xin Wu；Hyunseok Kang；Ivan H El-Sayed；Jonathan R George；Chase M Heaton；Ilya Likhterov；Mary Jue Xu；Patrick K Ha；Alain P Algazi；Katherine C Wai
作者单位	Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA. 查看其他 4 条单位信息 Department of Microbiology and Immunology, University of California San Francisco, San Francisco, California, USA.；Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.；Department of Medicine, Stanford University, Palo Alto, California, USA.；Department of Medicine, University of California San Francisco, San Francisco, California, USA.
期刊	Head & neck
SCI 分区	Q1
IF	2.5
研究类型	临床研究 · 临床
所属专科	咽喉科

中文摘要

背景： 他汀类药物可能调节免疫功能并增强免疫治疗反应。本研究评估了他汀类药物使用与接受帕博利珠单抗治疗的复发或转移性头颈部鳞状细胞癌（HNSCC）患者结局之间的关系。
方法： 在UCSF进行了一项回顾性观察性研究，纳入2016年至2022年接受帕博利珠单抗治疗的口腔、口咽、下咽、喉或皮肤HNSCC患者。主要结局为6个月无进展生存期（PFS）；次要结局为2年总生存期（OS）。
结果： 在165例患者中，60例（36%）使用他汀类药物。在调整ECOG状态、同期全身治疗和肿瘤部位后，任何他汀类药物使用（HR 0.49，p = 0.012）、高强度他汀类药物（HR 0.46，p = 0.012）和亲脂性他汀类药物使用（HR 0.54，p = 0.041）均与6个月PFS改善相关。
结论： 他汀类药物使用，尤其是高强度方案，与HNSCC患者接受帕博利珠单抗治疗的短期结局改善相关。有必要开展前瞻性研究以阐明潜在机制。

英文摘要

BACKGROUND: Statins may modulate immune function and enhance immunotherapy response. This study evaluated the relationship between statin use and outcomes in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) receiving pembrolizumab.
METHODS: A retrospective observational study was conducted at UCSF including patients with oral cavity, oropharyngeal, hypopharyngeal, laryngeal, or cutaneous HNSCC treated with pembrolizumab from 2016 to 2022. Primary outcome was 6-month progression-free survival (PFS); secondary was 2-year overall survival (OS).
RESULTS: Among 165 patients, 60 (36%) used statins. After adjustment for ECOG status, concurrent systemic therapy, and tumor site, any statin use (HR 0.49, p = 0.012), high-intensity statins (HR 0.46, p = 0.012), and lipophilic statin use (HR 0.54, p = 0.041) were associated with improved 6-month PFS.
CONCLUSIONS: Statin use, particularly high-intensity regimens, was associated with improved short-term outcomes on pembrolizumab in HNSCC. Prospective studies are warranted to elucidate underlying mechanisms.